Tenax Therapeutics Inc (Tenax) is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutic products for serious cardiovascular and pulmonary diseases. The company's lead product includes levosimendan(TNX-103), a calcium sensitizer developed for the treatment of patients with pulmonary hypertension associated with heart failure with PH-HFpEF. It also develops imatinib (TNX-201), a tyrosine kinase inhibitor, for the treatment of chronic myeloid leukemia. The company offers products in capsule and solid dosage forms. It partners with pharmaceutical companies to market products in the US and worldwide. Tenax is headquartered in Morrisville, North Carolina, the US.
Headquarters
United States of America
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, 27517
Website
www.tenaxthera.com
Telephone
1 919 8552100
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TENX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
30.2%
(2022 vs 2021)
Market Cap*
$7.1M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Tenax Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| TNX-201 (oral enteric coated imatinib) |
| TNX-103 (oral levosimendan) |
Competitor Comparison
| Key Parameters | Tenax Therapeutics Inc | Merck & Co Inc | AbbVie Inc | Amicus Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Chapel Hill | Kenilworth | North Chicago | Philadelphia |
| State/Province | North Carolina | New Jersey | Illinois | Pennsylvania |
| No. of Employees | 5 | 72,000 | 50,000 | 517 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gerald Proehl | Chairman | Executive Board | 2021 | 64 |
| Christopher T. Giordano | Director; Chief Executive Officer; President | Executive Board | 2021 | 49 |
| Stuart Rich | Chief Medical Officer; Director | Executive Board | 2021 | 73 |
| Douglas Hay | Senior Vice President - Regulatory Affairs | Senior Management | - | - |
| Eliot M. Lurier | Interm-Chief Financial Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer